6:16 PM
 | 
Dec 19, 2011
 |  BC Extra  |  Clinical News

Trius reports tedizolid data in ABSSSI

Trius Therapeutics Inc. (NASDAQ:TSRX) said once-daily oral tedizolid met the primary endpoint of non-inferiority to twice-daily oral linezolid in the proportion of patients who achieved a clinical response...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >